May 15, 2020

Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies

Journal of Clinical and Experimental Hematopathology : JCEH
Kensuke Kojima, Jan A Burger

Abstract

Treatment for patients with chronic lymphocytic leukemia (CLL) is becoming more individualized due to the recent introduction of novel molecularly targeted therapies into the therapeutic armamentarium. Genomic and molecular risk factors in CLL patients determine the individual risk for disease progression and response to therapy, and can impact survival. In this review article, we discuss current treatment strategies for CLL patients in Japan, where the novel targeted agents, the BTK inhibitor ibrutinib and BCL2 antagonist venetoclax, now are available and increasingly used in clinical practice. We also discuss the importance of CLL risk factors for making therapy decisions, focusing on immunoglobulin variable region heavy chain (IGHV) mutation status, 11q deletion, and 17p deletion. Treatment approaches for CLL have rapidly changed in the past few years because of these new targeted agents. They are highly effective, well tolerated, and have been demonstrated in a series of large randomized clinical trials to improve survival when compared with conventional chemotherapy-based treatment. Therefore, for most patients, especially high-risk CLL patients, BTK inhibitor and BCL2 antagonist therapies are preferred over chemo-immunoth...Continue Reading

  • References48
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Treatment Protocols
Chronic Lymphocytic Leukemia
Combined Modality Therapy
Immunotherapy
Clinical Trials, Randomized
Immunoglobulin gamma-Chains
Decision
Operative Surgical Procedures
Agent
Study

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Oncology Research and Treatment
Othman Al-SawafM Hallek
Expert Opinion on Pharmacotherapy
Candida Vitale, Jan A Burger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John C ByrdJoseph M Flynn
© 2020 Meta ULC. All rights reserved